Bloomberg Markets & Finance via Youtube


Nov.16 — Moderna Inc. said its Covid-19 vaccine was 94.5% effective in a preliminary analysis of a large late-stage clinical trial. The company is now expected to apply for emergency authorization from the FDA. Bloomberg’s Drew Armstrong reports on “Bloomberg Surveillance.”

READ ALSO  Federal Reserve Board announces extension through March 31, 2021, for several of its lending facilities that were generally scheduled to expire on or around December 31